FDA, EMA recommend no new patients start Lilly sarcoma drug after trial flops
Lilly announced last week that the Phase III confirmatory trial for Lartruvo in soft-tissue sarcomas failed to confirm the benefit seen in the Phase II study that led to its accelerated approval.